![Beatriz Salvador](https://profiles-cardiff.imgix.net/attachments/1211?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Beatriz Salvador
Research Associate
Overview
My research focuses on the first events occurring in the development of pancreatic cancer.
Pancreatic cancer is an aggressive diesease with very poor prognosis, mainly due to its late diagnosis. Therefore, understanding how it develops is crucial to develop early detection tools and preventative treatments that improves patient survival.
My objective is to understand how cells that acquire mutations in the pancreas relate to their non-mutant neighbours to develop premalignant lesions.
Publication
2024
- Badder, L. et al. 2024. The αvβ6 integrin specific virotherapy, Ad5NULL-A20.FCU1, selectively delivers 2 potent “in-tumour” chemotherapy to Pancreatic Ductal Adenocarcinoma. British Journal of Cancer 131, pp. 1694-1706. (10.1038/s41416-024-02869-3)
2023
- Sanz-Castillo, B. et al. 2023. The MASTL/PP2A cell cycle kinase-phosphatase module restrains PI3K-Akt activity in an mTORC1-dependent manner. The EMBO Journal 42(2), article number: e110833. (10.15252/embj.2022110833)
2022
- Hidalgo, M. et al. 2022. A preclinical and phase Ib study of palbociclib plus nab-paclitaxel in patients with metastatic adenocarcinoma of the pancreas. Cancer Research Communications 2(11), pp. 1326–1333. (10.1158/2767-9764.CRC-22-0072)
2021
- Hill, W. et al. 2021. EPHA2-dependent outcompetition of KRASG12D mutant cells by wild-type neigbors in the adult pancreas. Current Biology 31(12), pp. 2550-2560., article number: E5. (10.1016/j.cub.2021.03.094)
2020
- Salvador, B. et al. 2020. CDK4/6 inhibitors impair recovery from cytotoxic chemotherapy in pancreatic adenocarcinoma. Cancer Cell 37(3), pp. 340-353. (10.1016/j.ccell.2020.01.007)
Articles
- Badder, L. et al. 2024. The αvβ6 integrin specific virotherapy, Ad5NULL-A20.FCU1, selectively delivers 2 potent “in-tumour” chemotherapy to Pancreatic Ductal Adenocarcinoma. British Journal of Cancer 131, pp. 1694-1706. (10.1038/s41416-024-02869-3)
- Sanz-Castillo, B. et al. 2023. The MASTL/PP2A cell cycle kinase-phosphatase module restrains PI3K-Akt activity in an mTORC1-dependent manner. The EMBO Journal 42(2), article number: e110833. (10.15252/embj.2022110833)
- Hidalgo, M. et al. 2022. A preclinical and phase Ib study of palbociclib plus nab-paclitaxel in patients with metastatic adenocarcinoma of the pancreas. Cancer Research Communications 2(11), pp. 1326–1333. (10.1158/2767-9764.CRC-22-0072)
- Hill, W. et al. 2021. EPHA2-dependent outcompetition of KRASG12D mutant cells by wild-type neigbors in the adult pancreas. Current Biology 31(12), pp. 2550-2560., article number: E5. (10.1016/j.cub.2021.03.094)
- Salvador, B. et al. 2020. CDK4/6 inhibitors impair recovery from cytotoxic chemotherapy in pancreatic adenocarcinoma. Cancer Cell 37(3), pp. 340-353. (10.1016/j.ccell.2020.01.007)
Biography
I finished my BSc in Biology at Universidad de Alcalá (Alcalá de Henares, Spain) in 2013, and then moved to San Pablo CEU University (Madrid, Spain) to study my MSc in Clinic Research Applied to Oncology (2013-2014).
I joined Dr. Melchor Álvarez de Mon lab as Research Assistant in 2012 and collaborated in a project to characterize Recent Thymic Emigrants in Reumathoid Artritis patients treated with Rituximab.
In 2014 I started my PhD at the Spanish National Cancer Research Institute (CNIO) supervised by Dr. Manuel Hidalgo and Dr. Marcos Malumbres, too study CDK4/6 inhibitors in combination with standard chemotherapies for the treatment of pancreatic cancer. After finishing my PhD, I did a short 5-month postdoc at Malumbres lab.
Finally, in 2019 I moved to Cardiff University to Hogan lab where I am studying cell competition in pancreatic cancer initiation.
Contact Details
+44 29206 88506
Hadyn Ellis Building, Room ECSCRI, Maindy Road, Cardiff, CF24 4HQ